Lakefront Biotherapeutics (GLPGF) Other Non-Current Liabilities (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Other Non-Current Liabilities for 14 consecutive years, with $16.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 43.33% year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 43.33% decrease from a year earlier, with the FY2025 full-year figure at $14.2 million, down 61.11% from the prior year.
• Other Non-Current Liabilities was $16.1 million for Q1 2026 at Lakefront Biotherapeutics, up from $14.7 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $22.2 billion in Q4 2022 and troughed at $10.7 million in Q1 2022.
• A 5-year average of $1.7 billion and a median of $28.5 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 172.59% in 2022 and slumped 99.85% in 2023, its largest moves.
• Over 5 years, Other Non-Current Liabilities stood at $22.2 billion in 2022, then tumbled by 99.85% to $34.0 million in 2023, then gained by 6.4% to $36.1 million in 2024, then sank by 59.41% to $14.7 million in 2025, then advanced by 10.03% to $16.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $16.1 million (Q1 2026), $14.7 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.